188 related articles for article (PubMed ID: 15550845)
1. Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy.
Ogawa Y; Moriya T; Kato Y; Oguma M; Ikeda K; Takashima T; Nakata B; Ishikawa T; Hirakawa K
Breast Cancer; 2004; 11(3):267-75. PubMed ID: 15550845
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information.
Biesterfeld S; Schröder W; Steinhagen G; Koch R; Veuskens U; Schmitz FJ; Handt S; Böcking A
Anticancer Res; 1997; 17(6D):4723-9. PubMed ID: 9494596
[TBL] [Abstract][Full Text] [Related]
3. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
4. [Immunohistochemical detection of pS2 protein in paraffin sections of breast carcinoma tissue. Comparison with results of an immunoradiometry assay].
Ahr A; Scharl A; Göhring UJ; Crombach G; Stoffl M
Pathologe; 1995 Jul; 16(4):278-84. PubMed ID: 7667210
[TBL] [Abstract][Full Text] [Related]
5. Proportion of estrogen or progesterone receptor expressing cells in breast cancers and response to endocrine therapy.
Honma N; Horii R; Iwase T; Saji S; Younes M; Ito Y; Akiyama F
Breast; 2014 Dec; 23(6):754-62. PubMed ID: 25176593
[TBL] [Abstract][Full Text] [Related]
6. Quantitative progesterone receptor expression and efficacy of anti-estrogen therapy in breast cancer.
Luoh SW; Ramsey B; Park B; Keenan E
Breast J; 2014; 20(1):46-52. PubMed ID: 24261828
[TBL] [Abstract][Full Text] [Related]
7. Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma.
Fisher ER; Anderson S; Dean S; Dabbs D; Fisher B; Siderits R; Pritchard J; Pereira T; Geyer C; Wolmark N
Cancer; 2005 Jan; 103(1):164-73. PubMed ID: 15565575
[TBL] [Abstract][Full Text] [Related]
8. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.
Leers MP; Hoop JG; van Beers M; van Rodijnen N; Pannebakker M; Nap M
Cytometry B Clin Cytom; 2005 Mar; 64(1):43-52. PubMed ID: 15668953
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical detection of estrogen and progesterone receptors in primary breast cancer.
Chariyalertsak S; Chariyalertsak S; Ruangvejvorachi P
Asian Pac J Allergy Immunol; 1998 Dec; 16(4):161-6. PubMed ID: 10219897
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer.
Yamashita H; Yando Y; Nishio M; Zhang Z; Hamaguchi M; Mita K; Kobayashi S; Fujii Y; Iwase H
Breast Cancer; 2006; 13(1):74-83. PubMed ID: 16518065
[TBL] [Abstract][Full Text] [Related]
11. Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis.
Ba JL; Liu CG; Jin F
Asian Pac J Cancer Prev; 2014; 15(21):9233-9. PubMed ID: 25422206
[TBL] [Abstract][Full Text] [Related]
12. The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone.
Campbell EJ; Tesson M; Doogan F; Mohammed ZMA; Mallon E; Edwards J
Br J Cancer; 2016 Oct; 115(8):967-973. PubMed ID: 27657341
[TBL] [Abstract][Full Text] [Related]
13. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.
Van Calster B; Vanden Bempt I; Drijkoningen M; Pochet N; Cheng J; Van Huffel S; Hendrickx W; Decock J; Huang HJ; Leunen K; Amant F; Berteloot P; Paridaens R; Wildiers H; Van Limbergen E; Weltens C; Timmerman D; Van Gorp T; Smeets A; Van den Bogaert W; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 Jan; 113(1):181-7. PubMed ID: 18264760
[TBL] [Abstract][Full Text] [Related]
14. Estrogen and progesterone receptors in breast cancer: comparison between enzyme immunoassay and computer-assisted image analysis of immunocytochemical assay.
Cavaliere A; Bucciarelli E; Sidoni A; Bianchi G; Pietropaoli N; Ludovini V; Vitali R
Cytometry; 1996 Sep; 26(3):204-8. PubMed ID: 8889392
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing the prognostic role of oestrogen and progesterone receptor levels in breast cancer--results of the analysis of 670 patients with 11 years of follow-up.
Costa SD; Lange S; Klinga K; Merkle E; Kaufmann M
Eur J Cancer; 2002 Jul; 38(10):1329-34. PubMed ID: 12091062
[TBL] [Abstract][Full Text] [Related]
16. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters.
Thike AA; Chng MJ; Fook-Chong S; Tan PH
Pathology; 2001 Feb; 33(1):21-5. PubMed ID: 11280603
[TBL] [Abstract][Full Text] [Related]
18. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer.
Fisher B; Redmond C; Brown A; Wickerham DL; Wolmark N; Allegra J; Escher G; Lippman M; Savlov E; Wittliff J
J Clin Oncol; 1983 Apr; 1(4):227-41. PubMed ID: 6366135
[TBL] [Abstract][Full Text] [Related]
19. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
[TBL] [Abstract][Full Text] [Related]
20. Progesterone receptor quantification as a strong prognostic determinant in postmenopausal breast cancer women under tamoxifen therapy.
Lamy PJ; Pujol P; Thezenas S; Kramar A; Rouanet P; Guilleux F; Grenier J
Breast Cancer Res Treat; 2002 Nov; 76(1):65-71. PubMed ID: 12408377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
